Sang-We Kim

机构：Ulsan College, Asan Medical Center, University of Ulsan

发表论文 67 篇 · 总被引 11079 次 · h-index 30

代表论文

• Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials (2019 · The Lancet Oncology · 被引 545)
• Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study (2020 · The Lancet Oncology · 被引 419)
• Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study (2019 · Journal of Clinical Oncology · 被引 406)
• Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial (2019 · Journal of Thoracic Oncology · 被引 146)
• A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer (2020 · British Journal of Cancer · 被引 74)
• Preventing Infusion-Related Reactions With Intravenous Amivantamab—Results From SKIPPirr, a Phase 2 Study: A Brief Report (2025 · Journal of Thoracic Oncology · 被引 37)